BUSINESS
Syngene: Preferred CRAMS play for the long term
The company’s underperformance, compared to the Nifty, is not justified, and there is merit in considering the stock at the current levels. In the medium term, complex APIs and biologics manufacturing would be the growth drivers.
BUSINESS
Ami Organics: Multiple growth catalysts taking shape
Ami Organics is making its mark in the niche segments of chemicals having applications in lithium-ion batteries and semiconductors.
BUSINESS
Innova Captab IPO: A pricey contract manufacturer
The prime driver of growth is the volume visibility from contract duration, which is typically in the range of 2-5 years
BUSINESS
Equity strategy: Is a spoiler in the making for the Santa Claus rally?
The emerging Suez trade channel crisis might rekindle inflation fears. Advanced economies are already facing a sharp deceleration in growth indicators
BUSINESS
Fed policy: Dot plot suggests a pivot towards rate cuts
Domestic interest sensitive sectors can have positive rub-off
BUSINESS
Is the time ripe to add position in this chemical stock?
The company stands out due to the contractual nature of some of its businesses despite an adverse demand-supply situation
BUSINESS
Mandatory ACs in trucks: Multiple companies to benefit from the move
With the outlook for commercial vehicles remaining positive, Subros, Amber, SRF, and Navin Flurine will be gainers
BUSINESS
Himadri Speciality: Carbon companies scouting for new growth levers
Announces plan to set up India’s first commercial plant for Lithium Ion Phosphate Cathode Active Material.
BUSINESS
Balaji Amines: How long would destocking continue?
While the company may face pricing pressure in the next few quarters, it continues to target new products under the import substitution strategy. This augurs well for investors
BUSINESS
Equity strategy — How will the market react to state election results?
Improved political stability is a positive factor indeed, but elevated valuations mean they will seek support in earnings momentum even though global volatility lurks in the background
BUSINESS
PCBL: Do the unrelated M&As dampen the investment argument?
The company’s strategy to “future-proof” product profile is sensible but execution is key to the success of this endeavour
BUSINESS
Why are the US Fed and Street having divergent views?
It is prudent for investors to bet on the resilient domestic earnings story
BUSINESS
Concord Biotech: Operating leverage in play; accumulate for the long haul
This leading fermentation play on APIs is a worthy watch, given the scope for a ramp-up in new facilities, foray into injectables and a strong balance sheet.
BUSINESS
Are equities factoring in soft landing? What can go wrong?
Central banks are trying to bring inflation further down and a soft-landing doesn’t look certain as yet
BUSINESS
Galaxy Surfactants: signs of broad-based volume growth
The company exudes confidence on the back of its execution record and its defensive business profile, unlike peers in the chemical industry.
BUSINESS
Ami Organics: Fermion contract raises FY25 earnings visibility
Capex in Ankleshwar, pick-up in supplies for Fermion and a foray into the electro-lyte additive business are the other factors prompting the company to expect a bounce-back in growth in FY25.
BUSINESS
Does Aarti’s result suggest a turnaround for the chemical sector?
While the Indian chemicals industry remains a multi-decade opportunity and Aarti Industries is among the front runners, it faces many challenges in the short run.
BUSINESS
Zydus Lifesciences: Why we are getting constructive
There is a steady progress in product approvals and clinical trials for Zydus' niche products meant for rare ailments
BUSINESS
Divi’s Lab: FY25 to witness sizeable improvement in performance
The company is enthusiastic about the opportunities in contrast media and peptide building blocks, which shall unfold in 2-5 years
BUSINESS
Sun Pharma: Premium valuation caps upside
Progress in the Specialty pipeline will be a key watch as the company has stepped up R&D investments
BUSINESS
What should investors do after Fed's latest policy call?
The elevated yield curve has definitely tightened financial conditions, its persistence is difficult to gauge. However, the longer the yields remain at current levels, the more adverse will be the case for equities
BUSINESS
Navin Fluorine: Marred by delays, but still not off the radar
Other than supply-side factors, global demand is not encouraging and thus dims near-term prospects.
BUSINESS
Dr Reddy’s – Inorganic initiatives in India are a key watch
Steady quarterly results backed by traction in advanced economies
BUSINESS
SRF: Global demand fragile, value emerging
While the company faces a cyclical slowdown, it appears to be doing better than peers and the capex intensity remains focused on long-term opportunities.
